ipharmacenter Consulting services

AstraZeneca’s Imfinzi (durvalumab) has received approval in the United States as part of the first and only immunotherapy-based combination regimen for adults with previously untreated, high-risk non-muscle-invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin (BCG). The approval allows the use of Imfinzi alongside both induction and maintenance BCG therapy in this patient population. The regulatory decision is supported by findings from the Phase III

CVS Caremark is repositioning its GLP-1 weight management strategy to focus on both affordability and broader access, instead of simply expanding coverage as a routine update. The key operational moves are the reintroduction of Zepbound (tirzepatide) as a preferred option on its commercial formularies from October 1, 2026, and the removal of the new-to-market block on Foundayo (orforglipron), an oral GLP-1 therapy, effective June 1, 2026. These decisions indicate that CVS Car